

Research & Innovation

2024-2025 Annual Performance and Strategy Update

We are pleased to present the 2024/25 annual performance and strategy update for Research and Innovation

The Research and Innovation team is responsible for developing and supporting a varied research portfolio and ensuring better opportunities for patients and staff to participate in research activity, whilst informing the provision of high-quality, evidence-based health care.


The focus for R&I in 2024/25 is to continue growing a balanced research portfolio, including attracting increased activity from commercial sponsors. The research activity will be reviewed regularly, with bi-annual reporting to the Trust board and monthly reporting to Divisional teams and research investigators.

The R&I strategy 2022-2027, 'Research is for Everyone' sets out a clear vision to make research part of our daily business, realising the research potential in all areas of our hospitals for the benefit of patients, staff, and our community. This includes 4 key pillars: Place, Progress, People, and Partnership. This report provides an update on recruitment activity and progress against the key strategic objectives for year 2 and 3.




Performance

FY 2024 - 2025 Cumulative Monthly Recruitment




Recruitment

Annual recruitment over five years




Recruitment 23-24 & 24-25 at Q4



Performance

Total studies open & in follow-up 2024 – 2025, Q4 (Data cut: 14/03/2025)



	Open	In follow-up
Anaesthetics	1	3
Audiology	0	0
Cardiology	2	3
Critical Care	7	1
Dermatology	4	3
Diabetes	1	0
Emergency Care	3	0
Endocrine	0	0
ENT	2	0
Gastroenterology	4	7
Geriatrics	4	1
Haematology	3	2
Health Services	2	2
Hepatology	0	2
Histology	0	0
Mental Health	1	1
Microbiology	0	0
Neurology	1	1
Obs & Gynae	7	4
Oncology	14	11
Ophthalmology	1	0
Orthopaedic	2	2
Paediatrics	4	7
Renal	0	1
Respiratory	9	1
Rheumatology	7	1
Stroke	4	3
Urology	0	0
Surgery	4	3


Portfolio Management

Number of Studies
Opening FY 2024 –
2025:

28

Number of Studies
Closing FY 2024 –
2025:

18



Number of Studies
Actively Recruiting
FY 2024 – 2025:

97

Finance

2024/25

RRDN East Midlands Income

Budget **£904,178.51**

RRDN Bids: **£33,500**

2024/25

Q1-3 Commercial Income £161,558.04

For re-investment into future
research capability
and capacity
across SFH

**Department of
Health Funding**

£50,000

To maintain research
capability and capacity

Patient Research Experience



FY 2024/2025
Responses: 82

Preventing ill health



31



19

Work collaboratively with the community



16

Health Inequalities

15



Increase in Healthy Life Years

15



Productivity & Value for Money

10



Delivering digital care

8



Reduce overall length of stay

5



Reducing falls

4



Staff availability / Reducing workload pressures

3



Reduce bed occupancy

2



COPD/COVID/FLU/RSV Vaccine

2



Frailty

8

Improve Maternity Care



3



Hypertension / Cardiovascular

1



Early Cancer diagnosis

1



Smoking cessation

1



Staff retention

Our Research Impact

6 Publication and academic poster workshops attended by
21 staff



32 Individual NMAHP discussions to support new and innovative SFH-led research

6 Clinical academic workshops with clinical teams



32 SFH-wide Research Champions



4 NMAHP peer-reviewed publications

2 National / international conference presentations



2 Pump priming competition launch awarding projects



2 Nurses awarded NIHR research masters studentships

1 AHP awarded NHS/HEE research internship



2 SFH Consultant NMAHP-led research - developed, in progress

Strategy Update

	Progress	Place	People	Partnerships
Objectives	<p>1.1 Collaboration with EMRRDN & commercial sponsors to increase commercial research opportunities</p> <p>1.2 Streamline the SFH set-up process for faster delivery</p> <p>1.3 Engage with ICS wide research partners to develop a Nottingham wide commercial study set up network</p>	<p>2.1 Open a new Clinical Research Facility at Kings Mill Hospital in 2023 for clinical trials of new drugs, devices, and diagnostics</p> <p>2.2 Secure SFH mobile research unit to deliver research across primary care settings and undertake "Research Ready" engagement with our communities</p> <p>2.3 Bid to be submitted for NIHR Capital call May 2025 for purchase of MRU</p>	<p>3.1 Re Launch the SFH Research Academy to include a clinical delivery and a clinical academic research arm and increase research opportunities for SFH staff</p> <p>3.2 Investment into our management workforce to ensure a sustainable future for research and future developments</p> <p>3.3 Research to be a fundamental element of NED role</p>	<p>4.1 Increase our academic and industry partnerships to maximise mutual benefits from collaboration</p> <p>4.2 Collaboration with Chesterfield Royal NHS Trust in securing and utilising the mobile research unit</p> <p>4.3 Pursuing NTU collaboration as part of EMERGE bid</p>
Risks	<p>1.1 Reduction in access to novel interventions and medicines. Loss of income, reputation, and future growth as a research system partner</p> <p>1.2 Loss of repeat business, reduction in portfolio size. Failure to meet CRN targets</p> <p>1.3 Inability to consistently attract industry to the EM region</p>	<p>2.1 Significant impact on achieving objectives 1.1 and 4.1. Negative impact recruitment and retention and ability to fulfil our partnership with NUH for NIHR CRF bid 2027</p> <p>2.2 Unable to work efficiently across Mid Notts ICS and provide equity of access to research opportunities</p> <p>2.3 As 2.2, but also lack of response to the changing research landscape and popularity for de-centralised trials will have a negative impact on commercial activity</p>	<p>3.1 Unable to offer the development and training opportunities to SFH staff reducing research engagement and negative impact on SFH research culture. Negative impact on staff satisfaction</p> <p>3.2 Inadequate career pathways for research staff, impact on recruitment and retention. Loss of expertise to develop R&I at SFH and staff to more research active organisations</p> <p>3.3 Missed opportunity to engage in high level leadership and promotion of SFH's growing positive research culture</p>	<p>4.1 Fail to secure and sustain business from industry and showcase SFH research capabilities, linked to 1.1. Reduced access to research expertise and training for our staff. Inability to be an equitable research partner across the system</p> <p>4.2 As 2.2 and 2.3</p> <p>4.3 Missed opportunity to co-create in the Med Tech space</p>
Progress	<p>IAOCR Bronze level accreditation annually for 3 years</p> <p>Increased recruitment into commercial studies - new sponsor relationships formed, and studies identified for the CRF/MRU</p> <p>New role funded by CRN; Commercial Research Link Nurse role</p>	<p>Building work to commenced Jan 2025 - due to be complete June 25</p> <p>Mobile Research Unit delivered 1st April 2025 - Early engagement with Integrated Neighbourhood working and communities in process.</p>	<p>Training lead post in place, qualified GCP trainer</p> <p>Lead Academic Research NMAHP - Significant impact in developing NMAHP clinical academic careers/opportunities</p> <p>Associate NED Research on Trust Board</p>	<p>Access to select platforms to showcase our capabilities</p> <p>Membership of the Global Advisory Board for GSCA IAOCR</p> <p>EMERGE bid successful-launched 1st April- Formal launch event May/June</p>